Balziva — Class III drug recall D-684-2013
Terminated recall by Teva Pharmaceuticals USA, Inc., reported 2013-07-17, distributed nationwide. Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was de
| Recall number | D-684-2013 |
|---|---|
| Product type | Drug |
| Classification | Class III |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Teva Pharmaceuticals USA, Inc., Sellersville, PA, United States |
| Recall initiated | 2013-03-15 |
| Classified | 2013-07-05 |
| Reported by FDA | 2013-07-17 |
| Terminated | 2014-04-10 |
| Distributed | Nationwide (US) |
| Quantity | 36,708 blister |
| Reason classes | chemical contamination, specification failure |
| NDC | 00555-9034, 00555-9034-58, 00555-9034-79 |
| Lot numbers | 33802100A, 33802266A, 33802832A |
| Expiration dates | 2013-03, 2013-08 |
Product
Balziva(TM) (norethindrone and ethinyl estradiol tablets, USP) 0.15 mg/0.03 mg, 28 day regimen, Rx only, Barr Laboratories, Inc., Pomona, NY --- NDC 0555-9034-58
Reason for recall
Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testing
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-684-2013. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.